


Remarks

The foregoing amendments to the specification are to insert the priority provisional application information, for which this application claims benefit. The Abstract has also been added as a separate sheet, and should be inserted following the claims in the specification.

The cancellation of claims 11-2, 20-21 and 26-27 are to reduce the number of claims for prosecution. The amendments to the claim 40 are to eliminate multiple dependencies and to place the claims in proper format. No new matter has been added.

Respectfully submitted,



John T. Prince
Attorney for Applicant
Reg. No. 43,019

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-3346
Encl.: Abstract

Date: February 10, 2006